Biomerica Inc (BMRA)

$0.5767

-0.01

(-1.59%)▲

Market is closed - opens 7 PM, 05 Jun 2024

Insights on Biomerica Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 1.71M → 1.01M (in $), with an average decrease of 21.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -1.13M → -1.91M (in $), with an average decrease of 30.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 46.9% return, outperforming this stock by 101.5%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.6% return, outperforming this stock by 163.7%

Performance

  • $0.55
    $0.61
    $0.58
    downward going graph

    5.17%

    Downside

    Day's Volatility :9.84%

    Upside

    4.92%

    downward going graph
  • $0.50
    $2.13
    $0.58
    downward going graph

    13.79%

    Downside

    52 Weeks Volatility :76.53%

    Upside

    72.77%

    downward going graph

Returns

PeriodBiomerica IncIndex (Russel 2000)
3 Months
-51.97%
0.0%
6 Months
-37.66%
0.0%
1 Year
-54.57%
0.0%
3 Years
-84.12%
-22.6%

Highlights

Market Capitalization
9.8M
Book Value
$0.46
Earnings Per Share (EPS)
-0.38
PEG Ratio
0.0
Wall Street Target Price
13.0
Profit Margin
-117.42%
Operating Margin TTM
-196.66%
Return On Assets TTM
-43.02%
Return On Equity TTM
-92.05%
Revenue TTM
5.4M
Revenue Per Share TTM
0.32
Quarterly Revenue Growth YOY
-8.5%
Gross Profit TTM
446.0K
EBITDA
-6.3M
Diluted Eps TTM
-0.38
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Biomerica Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 2154.2%

Current $0.58
Target $13.00

Company Financials

FY18Y/Y Change
Revenue
5.6M
↓ 3.93%
Net Income
-1.5M
↑ 61.34%
Net Profit Margin
-26.34%
↓ 10.65%
FY19Y/Y Change
Revenue
5.2M
↓ 6.53%
Net Income
-2.4M
↑ 63.26%
Net Profit Margin
-46.01%
↓ 19.67%
FY20Y/Y Change
Revenue
6.7M
↑ 28.69%
Net Income
-2.3M
↓ 2.26%
Net Profit Margin
-34.95%
↑ 11.06%
FY21Y/Y Change
Revenue
7.2M
↑ 7.57%
Net Income
-6.5M
↑ 176.57%
Net Profit Margin
-89.86%
↓ 54.91%
FY22Y/Y Change
Revenue
18.9M
↑ 162.14%
Net Income
-4.5M
↓ 29.96%
Net Profit Margin
-24.01%
↑ 65.85%
FY23Y/Y Change
Revenue
5.3M
↓ 71.71%
Net Income
-7.1M
↑ 57.58%
Net Profit Margin
-133.73%
↓ 109.72%
Q4 FY22Q/Q Change
Revenue
1.5M
↓ 9.5%
Net Income
-1.6M
↓ 21.52%
Net Profit Margin
-109.73%
↑ 16.8%
Q1 FY23Q/Q Change
Revenue
1.1M
↓ 25.0%
Net Income
-1.6M
↑ 1.46%
Net Profit Margin
-148.44%
↓ 38.71%
Q2 FY23Q/Q Change
Revenue
1.1M
↓ 0.29%
Net Income
-1.8M
↑ 8.63%
Net Profit Margin
-161.72%
↓ 13.28%
Q3 FY23Q/Q Change
Revenue
1.7M
↑ 54.57%
Net Income
-1.1M
↓ 36.84%
Net Profit Margin
-66.08%
↑ 95.64%
Q4 FY23Q/Q Change
Revenue
1.6M
↓ 8.52%
Net Income
-1.5M
↑ 33.13%
Net Profit Margin
-96.17%
↓ 30.09%
Q1 FY24Q/Q Change
Revenue
1.0M
↓ 35.1%
Net Income
-1.9M
↑ 27.27%
Net Profit Margin
-188.59%
↓ 92.42%
FY18Y/Y Change
Total Assets
5.2M
↑ 4.08%
Total Liabilities
896.8K
↑ 69.57%
FY19Y/Y Change
Total Assets
5.2M
↑ 0.44%
Total Liabilities
1.3M
↑ 40.99%
FY20Y/Y Change
Total Assets
17.3M
↑ 229.05%
Total Liabilities
3.0M
↑ 140.97%
FY21Y/Y Change
Total Assets
11.8M
↓ 31.52%
Total Liabilities
2.6M
↓ 14.93%
FY22Y/Y Change
Total Assets
11.4M
↓ 3.76%
Total Liabilities
3.0M
↑ 17.66%
FY23Y/Y Change
Total Assets
14.5M
↑ 27.08%
Total Liabilities
2.7M
↓ 10.48%
Q4 FY22Q/Q Change
Total Assets
9.9M
↓ 10.34%
Total Liabilities
2.7M
↓ 2.34%
Q1 FY23Q/Q Change
Total Assets
8.2M
↓ 17.13%
Total Liabilities
2.2M
↓ 16.53%
Q2 FY23Q/Q Change
Total Assets
14.5M
↑ 76.05%
Total Liabilities
2.7M
↑ 22.75%
Q3 FY23Q/Q Change
Total Assets
13.2M
↓ 8.54%
Total Liabilities
2.5M
↓ 10.22%
Q4 FY23Q/Q Change
Total Assets
11.8M
↓ 10.5%
Total Liabilities
2.4M
↓ 0.12%
Q1 FY24Q/Q Change
Total Assets
10.3M
↓ 12.59%
Total Liabilities
2.5M
↑ 3.51%
FY18Y/Y Change
Operating Cash Flow
-1.2M
↑ 62.44%
Investing Cash Flow
-130.3K
↑ 35.66%
Financing Cash Flow
1.3M
↑ 720.59%
FY19Y/Y Change
Operating Cash Flow
-2.2M
↑ 91.11%
Investing Cash Flow
-171.1K
↑ 31.27%
Financing Cash Flow
1.9M
↑ 47.37%
FY20Y/Y Change
Operating Cash Flow
-4.3M
↑ 91.51%
Investing Cash Flow
-118.9K
↓ 30.5%
Financing Cash Flow
12.4M
↑ 548.73%
FY21Y/Y Change
Operating Cash Flow
-5.3M
↑ 22.2%
Investing Cash Flow
-295.6K
↑ 148.54%
Financing Cash Flow
1.1M
↓ 91.0%
FY22Y/Y Change
Operating Cash Flow
-480.5K
↓ 90.85%
Investing Cash Flow
-170.3K
↓ 42.37%
Financing Cash Flow
2.4M
↑ 115.0%
FY23Y/Y Change
Operating Cash Flow
-5.5M
↑ 1039.15%
Investing Cash Flow
-78.0K
↓ 54.21%
Financing Cash Flow
9.4M
↑ 292.15%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.2M
↓ 22.89%
Investing Cash Flow
-24.5K
↓ 27.21%
Financing Cash Flow
238.1K
↓ 86.6%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.7M
↑ 42.17%
Investing Cash Flow
-5.8K
↓ 76.46%
Financing Cash Flow
24.8K
↓ 89.61%
Q2 FY23Q/Q Change
Operating Cash Flow
-962.7K
↓ 44.19%
Investing Cash Flow
-14.1K
↑ 145.4%
Financing Cash Flow
7.3M
↑ 29595.41%
Q3 FY23Q/Q Change
Operating Cash Flow
-1.7M
↑ 73.89%
Investing Cash Flow
-63.0K
↑ 345.54%
Financing Cash Flow
-71.0K
↓ 100.97%

Technicals Summary

Sell

Neutral

Buy

Biomerica Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biomerica Inc
Biomerica Inc
-0.37%
-37.66%
-54.57%
-84.12%
-73.3%
Stryker Corporation
Stryker Corporation
4.27%
16.65%
22.1%
34.77%
82.03%
Boston Scientific Corp.
Boston Scientific Corp.
4.07%
37.57%
46.89%
79.16%
88.7%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.26%
26.96%
1.71%
-9.27%
51.45%
Abbott Laboratories
Abbott Laboratories
-2.62%
-2.21%
-0.86%
-5.87%
32.8%
Medtronic Plc
Medtronic Plc
0.44%
2.96%
-1.92%
-33.69%
-13.02%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biomerica Inc
Biomerica Inc
NA
NA
0.0
0.0
-0.92
-0.43
NA
0.46
Stryker Corporation
Stryker Corporation
38.89
38.89
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.5
63.5
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.45
37.45
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.83
31.83
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.48
29.48
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biomerica Inc
Biomerica Inc
Buy
$9.8M
-73.3%
NA
-117.42%
Stryker Corporation
Stryker Corporation
Buy
$129.9B
82.03%
38.89
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
88.7%
63.5
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
51.45%
37.45
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$177.8B
32.8%
31.83
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-13.02%
29.48
11.36%

Institutional Holdings

  • Granahan Investment Management Inc..

    6.71%

  • Wasatch Advisors LP

    5.67%

  • Vanguard Group Inc

    3.62%

  • Potomac Capital Management, Inc.

    1.00%

  • BlackRock Inc

    0.89%

  • Geode Capital Management, LLC

    0.72%

Company Information

biomerica, inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. the company’s products are designed to enhance health and well-being, while reducing total healthcare costs. biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing. the biomerica infoods® ibs product identifies patient specific foods that when removed may alleviate an individual's ibs symptoms. this patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve irritable bowel syndrome (ibs) outcomes. the point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for wh

Organization
Biomerica Inc
Employees
62
CEO
Mr. Zackary S. Irani
Industry
Health Technology

Discover More

FAQs